LTGO Latigo Biotherapeutics
Latigo Biotherapeutics earnings company data as of 4:50 AM ET 10/23
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 3 Dec | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 3 Sep | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by LTGO's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $5M bought by 2 insiders
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
James B. Tananbaum DirectorBuy$2.5M 140,000 shares at $18.00 +7.5% to stakeTraded Aug 10 Filed Aug 10
Also filed in the last 12 months, not counted as buying or selling: 32 conversions.
SEC filings
Recent issuer filings from EDGAR, 11 shown.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.